NCT04355728View on ClinicalTrials.gov

Use of UC-MSCs for COVID-19 Patients

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

April 25, 2020

Primary Completion Date

October 31, 2020

Study Completion Date

October 31, 2020

Conditions
Corona Virus InfectionARDSARDS, HumanAcute Respiratory Distress SyndromeCOVID-19
Interventions
BIOLOGICAL

Umbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.

UC-MSC will be administered at 100x10\^6 cells/infusion administered intravenously in addition to the standard of care treatment.

OTHER

Vehicle + Heparin along with best supportive care

Best supportive care treatment per the treating hospital protocol.

Trial Locations (1)

33136

Diabetes Research Institute, University of Miami Miller School of Medicine, Miami

All Listed Sponsors
lead

Camillo Ricordi

OTHER

NCT04355728 - Use of UC-MSCs for COVID-19 Patients | Biotech Hunter | Biotech Hunter